Evidence map›Paper›PMID 42470254›Full record

ArticleAmerican journal of hematology2026

Acute Myeloid Leukemia Subtype-Specific Prognostic Value of NGS in the Setting of Intensive Chemotherapy.

Abiola Bolarinwa, Aref Al-Kali, Hassan B Alkhateeb, Abhishek A Mangaonkar, Antoine N Saliba, Mehrdad Hefazi Torghabeh, Aasiya Matin, Michelle A Elliott, Mark R Litzow, William J Hogan and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Abiola BolarinwaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0001-5812-1954
Aref Al-KaliDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-0824-3715
Hassan B AlkhateebDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-3609-8404
Abhishek A MangaonkarDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0003-2458-9887
Antoine N SalibaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0001-5134-7336
Mehrdad Hefazi TorghabehDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0001-8860-3380
Aasiya MatinDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Michelle A ElliottDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-7366-9886
Mark R LitzowDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-9816-6302
William J HoganDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-5841-4105
Mithun V ShahDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-5359-336X
Mrinal M PatnaikDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0001-6998-662X
Animesh PardananiDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-9084-4148
James M ForanDivision of Hematology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.ORCID https://orcid.org/0000-0003-1673-1708
Talha BadarDivision of Hematology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.ORCID https://orcid.org/0000-0003-1548-918X
Hermant S MurthyDivision of Hematology, Department of Medicine, Mayo Clinic, Jacksonville, Florida, USA.ORCID https://orcid.org/0000-0003-4534-4248
Nathan PunwaniDivision of Hematology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
Jeanne M PalmerDivision of Hematology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
Lisa Z SproatDivision of Hematology, Department of Medicine, Mayo Clinic, Scottsdale, Arizona, USA.
Dong ChenDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0001-7627-9560
Kaaren K ReichardDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Rong HeDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0001-6116-8163
David S ViswanathaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Cinthya J Zepeda-MendozaDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-0434-4965
Naseema GangatDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0002-9104-6172
Kebede H BegnaDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Ayalew TefferiDivision of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.ORCID https://orcid.org/0000-0003-4605-3821

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We examined the prognostic value of routine NGS data in newly diagnosed acute myeloid leukemia (AML) treated with intensive (7 + 3 backbone) induction, specified by AML subtype. A contemporary (2015-2025) series of 545 Mayo Clinic patients (median age 56 years, females 44%) was considered. Median follow-up was 49 months with 341 (63%) allogeneic hematopoietic stem cell transplantations (AHSCT) recorded. AML subtypes included core-binding factor (CBF; N = 72; 13%), primary non-CBF (N = 403; 74%), post-myelodysplastic syndromes (MDS) or post-myelodysplastic/myeloproliferative neoplasms (post-MDS-MDS/MPN; N = 28; 5%), post-MPN (N = 15; 3%), and therapy-related (t-AML; N = 27; 5%). Corresponding complete remission rates, with/without count recovery (CR/CRi), were 89%, 76%, 64%, 27%, and 78% (p < 0.01) and 5-year transplant-censored survival rates 68%, 57%, 21%, 0%, and 55% (p < 0.01). In multivariable analyses, the prognostic value of specific mutations was mostly limited to primary non-CBF AML where adverse karyotype (OR 1.9; p = 0.04) predicted inferior and FLT3-ITD (OR 0.4; p < 0.01) or NPM1

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsHigh-Throughput Nucleotide SequencingLeukemia, Myeloid, AcuteAdultFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedMutationNucleophosminPrognosisNPM1 protein, humanNucleophosminKRASprognosisresponsesurvivalTET2TP53

Identifiers

PMID42470254
PMCPMC13540303

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.